Margarita (Marga) Garcia Calvo
About Margarita (Marga) Garcia Calvo
Margarita (Marga) Garcia Calvo is a Senior Principal Scientist at Bristol Myers Squibb with extensive experience in biochemistry and molecular biology.
Current Role at Bristol Myers Squibb
Margarita (Marga) Garcia Calvo holds the position of Senior Principal Scientist at Bristol Myers Squibb in New Jersey, United States. In this role, she is involved in high-level scientific research and development initiatives, contributing to the company's mission of discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.
Previous Experience at Lodo Therapeutics
From 2019 to 2020, Marga Garcia Calvo served as Team Lead- In Vitro Pharmacology at Lodo Therapeutics Corporation in the Greater New York City Area. During her tenure, she led a team focused on the development and execution of in vitro pharmacological assays, contributing to the advancement of the corporation's drug discovery efforts.
Extensive Tenure at Merck
Marga Garcia Calvo spent a significant portion of her career at Merck, holding various research and leadership positions. She joined Merck in 1994 as a Senior Research Biochemist and progressed through roles such as Research Fellow, Senior Research Fellow, Team Lead, and Principal Scientist over the course of 22 years. Her work spanned multiple therapeutic areas including atherosclerosis, immunology, neuroscience, thrombosis, fibrosis, hypertension, obesity, and diabetes.
Educational Background
Marga Garcia Calvo earned her Ph.D. in Biochemistry and Molecular Biology from Universidad Autónoma de Madrid. Her educational foundation laid the groundwork for her extensive career in scientific research and pharmacology, equipping her with the knowledge and skills necessary for her various roles in the pharmaceutical industry.
Specific Contributions and Discoveries
Throughout her career, Marga Garcia Calvo has made notable scientific contributions. She played a key role in discovering that the target of Ezetimibe (ZETIA), a cholesterol absorption inhibitor, is Niemann-Pick C1 Like 1 (NPC1L1). Additionally, she developed radioligand binding assays for over 20 targets and led the development of multiple key assays for diverse therapeutic programs. She also holds one granted patent and has authored 70 publications in peer-reviewed scientific journals.